TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05997407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organic Conceptions mindset management program
Description: Organic Conceptions is a theoretical model and corresponding 9-step cognitive-based therapy program that enables people to understand where they are in their fertility journey, and provides them with coping strategies to reframe the painful emotional side effects of infertility. In addition to the 9-step program, there are mini-classes on the key triggers that people face when dealing with infertility.~The intervention consists of a series of assignments that participants in the intervention group will complete for a ten-week period. These assignments will take approximately three hours per week to complete. In addition, participants will complete biweekly live support group sessions led by certified coaches and will have the option to join a Facebook support group.
Study: NCT05214742

Intervention type: OTHER
Intervention: Diagnostic Test
Description: Molecular diagnosis carried out in the context of care

Intervention type: OTHER
Intervention: Diagnostic Test
Description: Molecular diagnosis carried out in the context of care

Intervention type: OTHER
Intervention: Diagnostic Test
Description: Molecular diagnosis carried out in the context of care
Study: NCT04809181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine in Combination With Venetoclax
Description: Azacitidine in combination with venetoclax
Study: NCT06055153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48+PD-1+platinum-based
Description: Phase I: Three subjects with HER2 overexpression (IHC 2+/3+) were initially enrolled. If dose-limiting toxicity (DLT) was observed in two of the three subjects, the study was continued from dose 1 to dose 2. If ≤1 DLT is observed in 3 subjects, continue to enroll 3 patients, and if ≤2 DLT is observed in 6 subjects, proceed to the second phase. If \> 2 cases of DLT are observed in 6 subjects, adjust to dose 2 for phase 2.~Dose 1: RC48 2.5mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks~Dose 2: RC48 2.0mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks~The second stage: sample size expansion stage. RP2D obtained at stage 1 continues to be enrolled in up to 20 patients until disease progression or intolerable toxicity occurs.
Study: NCT04668443

Intervention type: OTHER
Intervention: Graphical Informed Consent (GIC)
Description: The GIC (set of illustrations that complement the written information and consent form) will be proposed to prospective participants by researchers, systematically during the pre-test (stage 1). If the stage 1 shows no negative impact of the GIC on the consent process, the stage 2 will be implemented and the GIC will be proposed by researchers when they feel it could be beneficial for the participant.
Study: NCT04953962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg
Study: NCT04953962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg
Study: NCT05444946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone tablet and Itraconazole
Description: Oral prednisolone 0.5 mg/Kg body weight tapered over 4 months and oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. traconazole will be given for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral itraconazole
Description: Oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. Itraconazole will be given for 12 months
Study: NCT04591392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reSept ASD Occluder
Description: Transcatheter closure of secundum ASD using a permanent implant
Study: NCT06517238

Intervention type: OTHER
Intervention: There is no intervention
Description: Observal Study.There is no intervention

Intervention type: OTHER
Intervention: There is no intervention
Description: Observal Study.There is no intervention
Study: NCT04016012

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Local Zambian Foods
Description: Each week, participants in the intervention group will collect a pack of foodstuffs to last a week from the research site. The packs will be adjusted according to the weight of the participant and daily recommended allowances. Packaging of foodstuffs will be done in the food service lab at the Mukuba University. Instructions on how to prepare and use the food will be given to the participants. All food Items will be labelled diabetic food to avoid intra-household sharing.
Study: NCT06319794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimiralisib
Description: Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimiralisib
Description: Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 4 weeks
Study: NCT05323019

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychotherapy
Description: Participants will receive 8 remote therapy sessions conducted via phone or video, Therapy sessions consists of modules selected using a shared decision making process, tailored so that it is personally meaningful to each participant. Participants will also receive supportive text messages on selected days during the 28 day study.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants will continue to receive the therapy that their treating physician felt was appropriate at the time of enrolment in the study, These can include cognitive behavioural therapy, supportive psychotherapy or mindfulness, support groups, physical exercise or relaxation.

Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal Ketamine (esketamine)
Description: Intranasal Ketamine (esketamine) - participants will receive a dose of 56 mg for a maximum of 2 weeks, followed by 56 mg or 84 twice a week for a total of 8 doses during the 28 -day study

Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal Ketamine (esketamine)
Description: Intranasal Ketamine (esketamine) - participants will receive a dose of 56 mg for a maximum of 2 weeks, followed by 56 mg or 84 twice a week for a total of 8 doses during the 28 -day study
Study: NCT05034068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.15% bezaydamine hydrochloride.
Description: 0.15% bezaydamine hydrochloride was applied in oral mucosa in Patients with head and neck cancer under RT, CT treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low power laser with a wavelength of 870 nm
Description: the irradiations will be done three times a week using low power laser with a wavelength of 870 nm. The irradiation mode will be punctual and in contact, perpendicular to the oral mucosa. The power will be 60 mW, energy density of 6 J/cm2. Irradiation time will be 6 seconds per point based on the laser beam spot size of 0.55cm2
Study: NCT05811598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated ultra low lever red light
Description: Myopia indoor lighting therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated ultra low lever red light
Description: Myopia indoor lighting therapy
Study: NCT05202535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: Hospital-based aerobic exercise training for 15-30 minutes including pre and post-vitals assessment.~3x/week on alternate days for 8 weeks at 40-70% of HR Max

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Patient education and counseling with diet plan.Walking 3 days15min/day for 8 weeks
Study: NCT04996836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Next Generation Sequencing and Network Analysis
Description: Next Generation Sequencing and Network Analysis will profile genetic and epigenetic abnormalities in blood from patients with BC.
Study: NCT05406271

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopy
Description: Impantation of hip prosthesis with intraoperative fluoroscopy
Study: NCT06285370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Mogamulizumab will be administered at the dose of 1.0 mg/kg as an intravenous (iv) infusion over at least 1 hour on Days 1, 8, 15, and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. Each treatment cycle is set as 28 days. Subjects will continue the treatment of mogamulizumab until any of the criteria for study withdrawal is met.
Study: NCT05887362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Reflexology
Description: Reflexology is a well-known, safe, and noninvasive alternative medicine technique. It alludes to a treatment that is applied to particular areas of the hands and feet. The compression on the hands or feet serves as a sensor linked to particular body areas. These sensors are activated by the reflexology technique to improve blood flow, energize, relax, and maintain homeostasis.
Study: NCT06613308

Intervention type: DRUG
Intervention: Neoadjuvant immunotherapy combined with chemotherapy
Description: The treatment regimen consisted of a PD-1/PD-L1 monoclonal antibody in combination with a platinum-containing two-agent standard chemotherapy regimen administered every three weeks. Following two to four cycles of therapy, patients who demonstrated no evidence of disease progression were eligible for surgical resection, which was performed within three to four weeks after the conclusion of the last neoadjuvant therapy. Consolidation with a PD-1/PD-L1 monoclonal antibody was initiated within three to eight weeks after surgery and continued every three weeks. The efficacy of the treatment was evaluated according to the irRECIST criteria. Chemotherapy regimens were selected based on tumour histology and investigator judgement. In the event of poor tolerability, patients may switch between cisplatin or carboplatin treatments.

Intervention type: DRUG
Intervention: Neoadjuvant chemotherapy
Description: A platinum-containing two-agent standard chemotherapy regimen was administered every three weeks. Following a two-to-four-cycle therapy, if the patients were evaluated without progressive disease, patients undergo surgical resection within three to four weeks of the final neoadjuvant treatment. Postoperative adjuvant chemotherapy is then conducted in accordance with the recommended regimen outlined in the 2022 edition of the CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer. The efficacy of the treatment was evaluated in accordance with the RECIST 1.1 criteria.~The chemotherapy regimens were selected based on the tumor histology and the judgement of the investigators, in accordance with the standard clinical practice. In the event of poor tolerability, patients may switch between cisplatin or carboplatin treatments.
Study: NCT06613321

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory function tests before introduction of vasodilator therapy
Description: Respiratory function tests before introduction of vasodilator therapy with evaluation of the RV/TLC ratio.

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory function tests before introduction of vasodilator therapy
Description: Respiratory function tests before introduction of vasodilator therapy with evaluation of the RV/TLC ratio.

Intervention type: DIAGNOSTIC_TEST
Intervention: 3 month follow up evaluation of response to treatment.
Description: Follow up of patients at least 3 months after introduction of vasodilator therapy to determine response to treatment or absence of response.

Intervention type: DIAGNOSTIC_TEST
Intervention: 3 month follow up evaluation of response to treatment.
Description: Follow up of patients at least 3 months after introduction of vasodilator therapy to determine response to treatment or absence of response.
Study: NCT06386159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Intervention or Comprehensive Intervention Combined with Electrical vagus nerve stimulation
Description: Comprehensive intervention includes multidisciplinary collaboration, screening and assessment, oral sensory training, oral motor training, respiratory training, and feeding management. Transcutaneous electrical stimulation of the vagus nerve at the lateral neck was performed by rehabilitation therapists. The cervical vagus nerve accompanies the carotid artery and is located at the groove between the trachea and the sternocleidomastoid muscle, which can be located by touching the carotid pulse. The two electrodes were pasted along the path of the cervical vagus nerve.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Intervention or Comprehensive Intervention Combined with Electrical vagus nerve stimulation
Description: Comprehensive intervention includes multidisciplinary collaboration, screening and assessment, oral sensory training, oral motor training, respiratory training, and feeding management. Transcutaneous electrical stimulation of the vagus nerve at the lateral neck was performed by rehabilitation therapists. The cervical vagus nerve accompanies the carotid artery and is located at the groove between the trachea and the sternocleidomastoid muscle, which can be located by touching the carotid pulse. The two electrodes were pasted along the path of the cervical vagus nerve.
Study: NCT06239181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing Exercises
Description: The patients in the intervention group scheduled for angiography were administered the Beck Anxiety Scale, and then they underwent conscious, deep breathing exercises along with synchronized breathing training. The face-to-face teaching and application of the breathing exercises took an average of 15-20 minutes. Additionally, routine treatment was applied. For both the intervention and control groups, the Beck Anxiety Scale was administered again after the completion of the coronary angiography procedure, once stabilization was achieved.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no intervention/routine procedure
Description: Beck Anxiety Scale was administered to the control group before coronary angiography. No intervention was performed in between. The routine procedure of the hospital continued. Beck Anxiety Scale was administered again after leaving the procedure.
Study: NCT05351593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given Orally
Study: NCT06173518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AUTO1
Description: Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with anti-CD19 chimeric antigen receptor (CAR) T cells
Study: NCT05053971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Biopsy
Description: Undergo core needle biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO
Study: NCT05363956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salvadora
Description: The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salvadora
Description: The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eucalyptus Oil
Description: The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eucalyptus Oil
Description: The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
Study: NCT05382013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Patients will receive treatment of oral avatrombopag 20mg per day for the first 5 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Liver Support System
Description: Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Liver Support System
Description: Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive internal medical treatment.
Description: Patients will receive comprehensive internal medical treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive internal medical treatment.
Description: Patients will receive comprehensive internal medical treatment.
Study: NCT06402877

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
Study: NCT05589220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: Music therapy carried out with MUSIC CARE©

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement
Description: NRT: Nicotine Patch, Nicotine Gum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement
Description: NRT: Nicotine Patch, Nicotine Gum
Study: NCT05986422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: The treatment period consists of six weeks of daily intake of either Methylprednisolone or placebo (depending on randomization), followed by an additional six weeks of daily intake of open-label Methylprednisolone. During the study, follow-up assessments will be conducted at two points: at week 8 and week 20 from the start of each treatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: The treatment period consists of six weeks of daily intake of either Methylprednisolone or placebo (depending on randomization), followed by an additional six weeks of daily intake of open-label Methylprednisolone. During the study, follow-up assessments will be conducted at two points: at week 8 and week 20 from the start of each treatment phase.
Study: NCT05372107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-80308
Description: AG-80308 Eye Drop Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-80308
Description: AG-80308 Eye Drop Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-80308
Description: AG-80308 Eye Drop Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-80308
Description: AG-80308 Eye Drop Solution
Study: NCT06184035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-SN201
Description: Intravenous infusion
Study: NCT06117228

Intervention type: OTHER
Intervention: Data collection
Description: Data collection